Tango Therapeutics Inc (TNGX)
7.87
-0.02
(-0.25%)
USD |
NASDAQ |
May 07, 15:19
Tango Therapeutics Cash from Financing (TTM): 82.41M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 82.41M |
September 30, 2023 | 81.47M |
June 30, 2023 | 1.299M |
March 31, 2023 | 1.431M |
December 31, 2022 | 1.615M |
Date | Value |
---|---|
September 30, 2022 | 0.968M |
June 30, 2022 | 328.64M |
March 31, 2022 | 327.17M |
December 31, 2021 | 357.32M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.968M
Minimum
Sep 2022
357.32M
Maximum
Dec 2021
131.37M
Average
81.47M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Aquestive Therapeutics Inc | 3.974M |
2seventy bio Inc | 127.39M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |